CRAFA
PEPTIDE & COMPOUND ANALYSIS

CERTIFICATE OF ANALYSIS

Certificate of Analysis (COA)

No. CRF-2026-1063
Issued: 2026-10-05

Independent Peptide & Research-Compound Testing
14 Mill Lane, Cambridge, United Kingdom

PRODUCT IDENTIFICATION

PRODUCT	SKU / INTERNAL CODE	PRESENTATION
PT-141 10mg	CRF-PT14110MG	Lyophilised powder, 10mg vial
BATCH NUMBER	SAMPLE RECEIVED	PRODUCTION DATE
LOT-2610-063	2026-09-28	2026-09-25
ANALYSIS DATE	EXPIRY / RETEST DATE	MOLECULAR FORMULA
2026-10-03	2028-10-03	C50H68N14O10
MOLECULAR WEIGHT (G/MOL)	CAS	
1024.18	189691-06-3	

Research Use Only (RUO). Not for human or veterinary use, consumption, or clinical diagnosis.

ANALYTICAL METHOD — HPLC

INSTRUMENT	COLUMN	COLUMN TEMPERATURE
Agilent 1290	C18 4.6×150mm	35°C
MOBILE PHASE A	MOBILE PHASE B	FLOW RATE
0.1% TFA H2O	ACN	1.0 mL/min
DETECTION WAVELENGTH	INJECTION VOLUME	SAMPLE CONCENTRATION
214 nm	10 µL	1.0 mg/mL
DILUENT	RETENTION TIME (MAIN PEAK)	
—	8.7 min	

Recorded methods: HPLC-UV (214 nm) · LC-MS/MS · LAL · ICP-MS

RESULTS

Test	Acceptance Criteria	Result	Verdict
HPLC Purity (% area)	≥98.0%	99.4%	PASS
Identity (LC-MS)	1024.2 ±2%	Obs: 1024.4 [M+H]+	PASS

Test	Acceptance Criteria	Result	Verdict
Quantity found	95.0–105.0%	9.89 mg (98.9%)	PASS
Endotoxin	<1.0 EU/mg	<0.25 EU/mg	PASS
Heavy metals	<10 ppm	All <LOQ	PASS

Detected Impurities

No impurity data recorded.

FINAL BATCH RESULT

PASS — Conforms to specifications

No chromatogram data recorded.

Analyst notes: Category: Specialty. Sample conforms to label claim and Gold panel acceptance criteria.

crafa

CRAFA